ArticleJournal of molecular neuroscience : MN2012
Increased expression of α-synuclein by SNCA duplication is associated with resistance to toxic stimuli.
Article in Journal of molecular neuroscience : MN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Altered Sphingolipid Hydrolase Activities and Alpha-Synuclein Level in Late-Onset Schizophrenia.Metabolites · 2023Article
- Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease.Brain and behavior · 2021Review
- CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.Cellular and molecular neurobiology · 2020Review
- Overexpression of alpha-synuclein promotes both cell proliferation and cell toxicity in human SH-SY5Y neuroblastoma cells.Journal of advanced research · 2020Article
- Using induced pluripotent stem cells for modeling Parkinson's disease.World journal of stem cells · 2019Review
- Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression.Nature · 2016Article
- The role of quercetin on the survival of neuron-like PC12 cells and the expression of α-synuclein.Neural regeneration research · 2015Article
- Rotenone upregulates alpha-synuclein and myocyte enhancer factor 2D independently from lysosomal degradation inhibition.BioMed research international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duplication of alpha-synuclein gene (SNCA) is a recognized cause of Parkinson's disease (PD). However, the penetrance in families with SNCA duplication is as low as 30%, indicating that factors other than the SNCA gene dosage have an important role in neuronal death. In this study, using lymphoblastoid cell lines (LCLs) derived from a parkinsonian kindred with SNCA duplication, we examined whether there is difference in (1) the level of SNCA mRNA and protein expression and cell viability and (2) the vulnerability to various insults relevant to PD between a patient, asymptomatic carrier, and unaffected control. Expression of SNCA mRNA and protein increased in the LCLs from subjects with SNCA gene duplication, irrespective of the disease status. In the absence of treatment, LCLs from the patient and carrier showed decreased viability compared with the LCL from the control. The LCL from the patient also showed decreased viability compared to the carrier. When susceptibility to various insults including lactacystin, dexamethasone, 3-methyladenine, H(2)O(2), and rotenone was examined, surprisingly, the LCL from the patient was more resistant than the LCL from the control to all agents except for lactacystin. This study shows that both intrinsic and extrinsic factors and their interaction have important roles in cell death and in the development of PD and further indicates that the relationship between cell death and the level of alpha-synuclein may be more complicated than previously thought.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.